<DOC>
	<DOCNO>NCT00811005</DOCNO>
	<brief_summary>The purpose prospective , randomize , control , single-blinded investigation study efficacy , tolerability safety oral photochemotherapy ( PUVA ) combine acitretin versus oral PUVA combine systemic fumaric acid ester ( FAE ) patient pustular palmoplantar psoriasis . Patients randomize allocate concealed manner one two treatment arm : acitretin-PUVA FAE-PUVA .</brief_summary>
	<brief_title>Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy Pustular Palmoplantar Psoriasis</brief_title>
	<detailed_description>Acitretin-PUVA treatment schedule : Acitretin monotherapy : Patients randomize acitretin group receive acitretin dose 1mg /kg daily two week prior additional PUVA treatment . Acitretin-PUVA combination : PUVA treatment ( see ) apply thrice weekly addition acitretin ( near ) complete clearance maximum period 12 week . ( Near ) complete clearance define improvement clinical baseline score ( see ) ≥90 % . Acitretin maintenance therapy : After ( near ) complete clearance patient continue maintenance dose 0.5 mg/kg acitretin 6 month significant relapse . Significant relapse define worsen clinical score ≥50 % baseline score . Follow-up period : Patients still significantly improve ( clinical score &lt; 50 % baseline score ) follow significant relapse maximum period 12 month . Besides emollient additional specific treatment allow study . FAE-PUVA treatment schedule : FAE monotherapy : Patients randomize group receive FAE weekly incremental dos ( initial daily dose : 30 mg dimethylfumarate ( DMF ) , high daily dose : 720 mg DMF ) start two week prior additional PUVA treatment . FAE-PUVA combination : PUVA treatment apply thrice weekly addition FAE ( near ) complete clearance maximum period 12 week . ( Near ) complete clearance define improvement clinical baseline score ( see ) ≥90 % . FAE maintenance therapy : After ( near ) complete clearance FAE reduce weekly 120 mg DMF daily maintenance dose 360 mg DMF administer maximum period 6 month significant relapse . Significant relapse define worsen clinical score ≥50 % baseline score . Follow-up period : Patients still significantly improve ( clinical score &lt; 50 % baseline score ) follow significant relapse maximum period 12 month . Besides emollient additional specific treatment allow study . PUVA treatment : Intake 8-methoxypsoralen dose 0.6 mg/kg 1 hour UVA irradiation , case 8-methoxypsoralen intolerance , 5-methoxypsoralen dose 1.2 mg/kg 2 hour UVA irradiation . Start PUVA 2 week initiation acitretin FAE treatment . Irradiation give three time per week maximum period 12 week ( 36 exposure ) . PUVA exposure limit hand foot . Primary outcome measure : Duration remission Secondary outcome measure : Percentage patient achieve remission Number PUVA exposure require induce remission Total UVA exposure dose require inducing remission Frequency quality adverse reaction Assessment clinical response : A modified local PASI ( psoriasis area severity index ) score adapted evaluation hand foot perform blinded investigator baseline onset PUVA treatment , biweekly interval course PUVA treatment , monthly interval discontinuation PUVA bimonthly interval 1-year follow-up period . The study terminate case significant relapse define PASI score ≥50 % baseline score . Monitoring : Prior study blood chemistry , complete blood cell count include differential , urine analysis , TSH , TPO- TG autoantibody , pregnancy test ( woman childbearing potential ) ophthalmological examination perform . During study complete blood cell count , blood chemistry , urine analysis pregnancy test ( woman childbearing potential ) reexamine monthly .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Acitretin</mesh_term>
	<mesh_term>5-methoxypsoralen</mesh_term>
	<mesh_term>Methoxsalen</mesh_term>
	<criteria>Patients pustular palmoplantar psoriasis Patients older 18 year Pregnant lactating woman Uncontrolled hyperlipidemia Patients severely impaired hepatic function Patients severely impaired renal function Immunosuppression . Abnormal UVA sensitivity Intake photosensitizing drug Oral antipsoriatic therapy within last 4 week Topical antipsoriatic therapy within last 2 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>acitretin</keyword>
	<keyword>fumaric acid ester</keyword>
	<keyword>pustular palmoplantar psoriasis</keyword>
	<keyword>PUVA</keyword>
</DOC>